Application of immunotherapy in esophageal squamous cell carcinoma / 中华胸心血管外科杂志
Chinese Journal of Thoracic and Cardiovascular Surgery
;
(12): 681-687, 2022.
Article
Dans Chinois
| WPRIM
| ID: wpr-958461
ABSTRACT
Esophageal cancer is one of the top ten of the world's most common cancer. Although the incidence of esophageal squamous cell carcinoma (ESCC) in some high-risk areas in East Asia has being decreasing, it is still the most common histologic subtypes. A great many of patients with ESCC not only are diagnosed in an advanced stage but also have a high mortality rate. With the application of tumor immunotherapy in ESCC treatment in recent years, the prognosis of ESCC patients has been improved to a certain extent. This article intends to review the research progress of immunotherapy in esophageal squamous cell carcinoma.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
langue:
Chinois
Texte intégral:
Chinese Journal of Thoracic and Cardiovascular Surgery
Année:
2022
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS